|
Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting. |
|
|
|
|
|
Employment - Analysis Group |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Kiniksa (Inst); LivaNova (Inst); Mallinckrodt (Inst); Medtronic (Inst); Merck (Inst); Novartis (Inst); Novo Nordisk (Inst); Novo Nordisk (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Seagen (Inst); Takeda (Inst); ViiV Healthcare (Inst) |
|
|
|
Stock and Other Ownership Interests - AstraZeneca; Biogen; CVS; Johnson & Johnson |
Research Funding - Johnson & Johnson (I) |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Greenwich Biosciences; Novartis; Pfizer; Regeneron; Sanofi; Takeda |
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Greenwich Biosciences (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Epizyme (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Takeda (Inst); Teva (Inst); Vertex (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Kiniksa (Inst); MyoKardia (Inst); Pfizer (Inst); Vertex (Inst) |
|
|
Research Funding - AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |